Company Overview More
Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.
CEO: Poirier, Michael S.
Market: NASDAQ
Futu Hot List
USHKCN
Trade HeatSearch HeatNews Heat
SymbolLatest Price% Chg

Loading...

QLGN Qualigen Therapeutics

1.700-0.050-2.86%
Close 11/26 16:51 ET
1.690-0.01-0.59%
Post Mkt Price 11/26 16:56 ET
High
1.850
Open
1.668
Turnover
11.03M
Low
1.520
Prev.Close
1.750
Volume
6.65M
Market Cap
49.50M
P/E(TTM)
Loss
52Wk High
4.660
Shares
29.12M
P/E
Loss
52Wk Low
0.930
H Mkt Cap
45.17M
Bid-Ask Ratio
-61.70%
Historical High
21.475
H Shares
26.57M
Vol. Ratio
0.20
Historical Low
0.930
Dividend TTM
--
Div Yield TTM
--
P/B
4.57
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
25.03%
Amplitude
18.86%
Avg Price
1.658
Min Trading Unit
1
Float Market Cap
45.17M
Bid-Ask Ratio
-61.70%
Historical High
21.475
Float
26.57M
Vol. Ratio
0.20
Historical Low
0.930
Dividend TTM
--
P/B
4.57
Dividend LFY
--
Turnover Ratio
25.03%
Amplitude
18.86%
Avg Price
1.658
Min Trading Unit
1
Price Forecast

Loading...

News